Pharmaceutical Care Program for Type 2 Diabetes Mellitus (pcp)

November 3, 2015 updated by: TABREJ MUJAWAR

Evaluation of Pharmaceutical Care Program for Type 2 Diabetes Mellitus in Dhule

Evaluation of Pharmaceutical Care Program for Type 2 diabetes mellitus in Dhule

Objectives:-

  1. To evaluate Pharmaceutical care program in Type2 diabetics.
  2. To evaluate the impacts of Pharmaceutical care on quality of life (QOL) in patient with Type-2 Diabetes Mellitus.
  3. To study the prevalence of Type2 diabetics cases in Dhule.
  4. To study the Assessment of different type of adverse drug reactions (ADRs). In Type2 diabetics.
  5. To evaluate the Drug Drug intereaction in Type-2 Diabetes Mellitus.
  6. To study the impacts of Pharmaceutical care program on glycemic control in patients with Type-2 Diabetes Mellitus.
  7. To study the Drug utilization pattern in Type-2 Diabetes Mellitus in civil hospital Dhule.
  8. To compare the efficiency of Pharmaceutical care program and drug in patients with Type-2 Diabetes Mellitus.
  9. To study the Pharmaco-economic evaluation in Type-2 Diabetes Mellitus patient's.
  10. To increase the patient compliance and positive attitude of patients towards the diabetes disease by counseling.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

To evaluate the impacts of Pharmaceutical care on quality of life (QOL) in patient with Type-2 Diabetes Mellitus.

To study the prevalence of Type2 diabetics cases in Dhule. To study the Assessment of different type of adverse drug reactions (ADRs). In Type2 diabetics.

To evaluate the Drug Drug intereaction in Type-2 Diabetes Mellitus.

Study Type

Interventional

Enrollment (Anticipated)

600

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • India
    • Maharashtra
      • Dhule, Maharashtra, India, 424001
        • Tabrej Aj Mujawar

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

35 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:Inclusion Criteria:

  • Patients with type 2 diabetes mellitus of either
  • Patients with HbA1c more than 7% and
  • Patients with blood sugar level more than 140 mg / dl

Exclusion Criteria:

  • Patient with end stage kidney disease.
  • Patient with heart failure.
  • Patient with chronic Diabetes problem and orthopedic problem

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: PHARMACEUTICAL CARE programe
The pharmaceutical care program was characterized by face to face monthly visits to collect information, register information, prepare plan of care for every health problem; identification of drug therapy problems, communication to prescribers the drug therapy problems identified and education of participants to resolve the drug therapy problems.
Other: PHARMACEUTICAL CARE programe
The pharmaceutical care program was characterized by face to face monthly visits to collect information, register information, prepare plan of care for every health problem; identification of drug therapy problems, communication to prescribers the drug therapy problems identified and education of participants to resolve the drug therapy problems.
Other: control
without pharmaceutical care programe (control)
Other: Without PHARMACEUTICAL CARE programe

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Fasting blood glucose measurements recorded (mg/dl).Postprandial blood glucose Recorded: Fasting blood glucose measurements recorded (mg/dl).Postprandial bloodglucoseRecorded
Time Frame: 24 weeks
Fasting blood glucose measurements recorded (mg/dl).Postprandial blood glucose Recorded Fasting blood glucose measurements recorded (mg/dl).Postprandial blood glucose Recorded fasting blood glucose
24 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Quality of Life score
Time Frame: 24 weeks
Quality of Life score
24 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

TABREJ MUJAWAR

Investigators

  • Principal Investigator: tabrej aj mujawar, mpharm, muhs

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

July 1, 2012

Primary Completion (Actual)

June 1, 2015

Study Completion (Actual)

November 1, 2015

Study Registration Dates

First Submitted

February 7, 2015

First Submitted That Met QC Criteria

May 5, 2015

First Posted (Estimate)

May 6, 2015

Study Record Updates

Last Update Posted (Estimate)

November 4, 2015

Last Update Submitted That Met QC Criteria

November 3, 2015

Last Verified

November 1, 2015

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • pc

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on DIABETES MELLITUS, TYPE 2

Clinical Trials on PHARMACEUTICAL CARE programe

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kazakhstan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe